Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors

Journal of Virology

Volumn 80, Issue 3, 2006, Pages 1067-1076

  Cullen, Bryan R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; CULLIN; CYTIDINE DEAMINASE; DNA GLYCOSYLTRANSFERASE; ELONGIN; GAG PROTEIN; IMMUNOGLOBULIN; RNA DIRECTED DNA POLYMERASE; SUPPRESSOR OF CYTOKINE SIGNALING; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANTIBIOTIC RESISTANCE; GENE CLUSTER; GENE DUPLICATION; HEPATITIS B VIRUS; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INNATE IMMUNITY; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; RETROPOSON; RETROVIRUS; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPUMA VIRUS; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; GENE PRODUCTS, VIF; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNITY, NATURAL; LEUKEMIA VIRUS, MURINE; MULTIGENE FAMILY; NUCLEOSIDE DEAMINASES; RETROVIRIDAE; RNA EDITING; SIMIAN IMMUNODEFICIENCY VIRUS; SPUMAVIRUS; VIRUS ASSEMBLY;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; MURINE LEUKEMIA VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SPUMAVIRUS;

EID: 31144469701     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.3.1067-1076.2006     Document Type: Short Survey

References (78)

1. Alce, T. M., and W. Popik. 2004. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279:34083-34086.
2. Berkowitz, R. D., A. Ohagen, S. Hoglund, and S. P. Goff. 1995. Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J. Virol. 69:6445-6456.
3. Bishop, K. N., R. K. Holmes, A. M. Sheehy, N. O. Davidson, S.-J. Cho, and M. H. Malim. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
4. Bogerd, H. P., B. P. Doehle, H. L. Wiegand, and B. R. Cullen. 2004, A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV-1 Vif. Proc. Natl. Acad. Sci. USA 101:3770-3774.
5. Bransteitter, R., P. Pham, M. D. Scharff, and M. F. Goodman. 2003. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl. Acad. Sci. USA 100:4102-4107.
6. Cen, S., F. Guo, M. Niu, J. Saadatmand, J. Deflassieux, and L. Kleiman. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279:33177-33184.
7. + T cells. Nature 435:108-114.
8. Conticello, S. G., R. S. Harris, and M. S. Neuberger. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013.
9. Cristofari, G., D. Ficheux, and J.-L. Darlix. 2000. The Gag-like protein of the yeast Ty1 retrotransposon contains a nucleic acid chaperone domain analogous to retroviral nucleocapsid proteins. J. Biol. Chem. 275:19210-19217.
10. Cullen, B. R. 1991. Human immunodeficiency virus as a prototypic complex retrovirus. J. Virol. 65:1053-1056.
11. Doehle, B. P., A. Schäfer, and B. R. Cullen. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339:281-288.
12. Doehle, B. P., A. Schäfer, H. L. Wiegand, H. P. Bogerd, and B. R. Cullen. 2005. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79:8201-8207.
13. Dutko, J. A., A. Schäfer, A. E. Kenny, B. R. Cullen, and M. J. Curcio. 2005. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr. Biol. 15:661-666.
14. Esnault, C., O. Heidmann, F. Delebecque, M. Dewannieux, D. Ribet, A. J. Hance, T. Heidmann, and O. Schwartz. 2005. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433:430-433.
15. Fitzgibbon, J. E., S. Mazar, and D. T. Dubin. 1993. A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retrovir. 9:833-838.
16. + T lymphocytes. J. Virol. 66:6489-6495.
17. 16a. Gaddis, N. C., A. M. Sheehy, K. M. Ahmad, C. M. Swanson, K. N. Bishop, B. E. Beer, P. A. Marx, F. Gao, F. Bibollet-Ruche, B. H. Hahn, and M. H. Malim. 2004. Further investigation of simian immunodeficiency virus Vif function in human cells. J. Virol. 78:12041-12046.
18. Haché, G., M. T. Liddament, and R. S. Harris. 2005. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280:10920-10924.
19. Harris, R. S., K. N. Bishop, A. M., Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
20. + T cells. J. Virol. 75:7973-7986.
21. Jarmuz, A., A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, J. Scott, and N. Navaratnam. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.
22. Jin, X., A. Brooks, H. Chen, R. Bennett, R. Reichman, and H. Smith. 2005. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79:11513-11516.
23. Kao, S., M. A. Khan, E. Miyagi, R. Plishka, A. Buckler-White, and K. Strebel. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407.
24. Kazazian, H. H., Jr. 2004. Mobile elements: drivers of genome evolution. Science 303:1626-1632.
25. Khan, M. A., S. Kao, E. Miyagi, H. Takeuchi, R. Goila-Gaur, S. Opi, C. L. Gipson, T. G. Parslow, H. Ly, and K. Strebel. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870-5874.
26. Kobayashi, M., A. Takaori-Kondo, K. Shindo, A. Abudu, K. Fukunaga, and T. Uchiyama. 2004. APOBEC3G targets specific virus species. J. Virol. 78:8238-8244.
27. Langlois, M.-A., R. C. L. Beale, S. G. Conticello, and M. S. Neuberger. 2005. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33:1913-1923.
28. Liddament, M. T., W. L. Brown, A. J. Schumacher, and R. S. Harris. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
29. Linial, M. L. 1999. Foamy viruses are unconventional retroviruses. J. Virol. 73:1747-1755.
30. Liu, B., P. T. N. Sarkis, K. Luo, Y. Yu, and X.-F. Yu. 2005. Regulation of APOBEC3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79:9579-9587.
31. Liu, B., X. Yu, K. Luo, Y. Yu, and X.-F. Yu. 2004. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2072-2081.
32. Löchelt, M., F. Romen, P. Bastone, H. Muckenfuss, N. Kirchner, Y.-B. Kim, U. Truyen, U. Rösler, M. Battenberg, A. Saib, E. Flory, K. Cichutek, and C. Münk. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. USA 102:7982-7987.
33. Luo, K., B. Liu, Z. Xiao, Y. Yu, X. Yu, R. Gorelick, and X.-F. Yu. 2004. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78:11841-11852.
34. Madani, N., and D. Kabat. 1998. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:10251-10255.
35. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
36. Mangeat, B., P. Turelli, S. Liao, and D. Trono. 2004. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279:14481-14483.
37. Mariani, R., D. Chen, B. Schröfelbauer, F. Navarro, R. König, B. Bollman, C. Münk, H. Nymark-McMahon, and N. R. Landau. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
38. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med. 9:1398-1403.
39. Mehle, A., J. Goncalves, M. Santa-Marta, M. McPike, and D. Gabuzda. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866.
40. Mehle, A., B. Strack, P. Ancuta, C. Zhang, M. N. McPike, and D. Gabuzda. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
41. Mietz, J. A., Z. Grossman, K. K. Lueders, and E. L. Kuff. 1987. Nucleotide sequence of a complete mouse intracisternal A-particle genome: relationship to known aspects of particle assembly and function. J. Virol. 61:3020-3029.
42. Mikl, M. C., I. N. Watt, M. Lu, W. Reik, S. L. Davies, M. S. Neuberger, and C. Rada. 2005. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 25:7270-7277.
43. Navarro, F., B. Bollman, H. Chen, R. König, Q. Yu, K. Chiles, and N. R. Landau. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386.
44. Newman, E. N. C., R. K. Holmes, H. M. Craig, K. C. Klein, J. R. Lingappa, M. H. Malim, and A. M. Sheehy. 2005. Anti-viral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
45. Ribeiro, A. C., A. Mala e Silva, M. Santa-Marta, A. Pombo, J. Moniz-Pereira, J. Goncalves, and I. Barahona. 2005. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J. Virol. 79:823-833.
46. Rose, K. M., M. Marin, S. L. Kozak, and D. Kabat. 2005. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum. Retrovir. 21:611-619.
47. Rosier, C., J. Kock, M. Kann, M. H. Malim, H. E. Blum, T. F. Baumert, F. Von Weizsacker. 2005. APOBEC-mediated interference with hepadnavirus production. Hepatology 42:301-309.
48. Russell, R. A., H. L. Wiegand, M. D. Moore, A. Schäfer, M. O. McClure, and B. R. Cullen. 2005. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79:8724-8731.
49. 47a. Sawyer, S. L., M. Emerman, and H. S. Malik. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2:1278-1285.
50. Schäfer, A., H. P. Bogerd, and B. R. Cullen. 2004. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163-168.
51. Schröfelbauer, B., D. Chen, and N. R. Landau. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectiviry factor (Vif). Proc. Natl. Acad. Sci. USA 101:3927-3932.
52. Schröfelbauer, B., Q. Yu, S. G. Zeitlin, and N. R. Landau. 2005. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79:10978-10987.
53. Schumacher, A. J., D. V. Nissley, and R. S. Harris. 2005. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. USA 102:9854-9859.
54. Seifarth, W., O. Frank, U. Zeilfelder, B. Spiess, A. D. Greenwood, R. Hehlmann, and C. Leib-Mösch. 2005. Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J. Virol. 79:341-352.
55. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
56. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
57. Simon, J. H. M., N. C. Gaddis, R. A. M. Fouchier, and M. H. Malim. 1998. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1397-1400.
58. Simon, J. H., and M. H. Malim. 1996. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleo-protein complexes. J. Virol. 70:5297-5305.
59. Simon, V., V. Zennou, D. Murray, Y. Huang, D. D. Ho, and P. D. Bieniasz. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6.
60. Stenbak, C. R., and M. L. Linial. 2004. Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression. J. Virol. 78:9423-9430.
61. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601.
62. Suspène, R., D. Guétard, M. Henry, P. Sommer, S. Wain-Hobson, and J.-P. Vartanian. 2005. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102:8321-8326.
63. Svarovskaia, E. S., H. Xu, J. L. Mbisa, R. Barr, R. J. Gorelick, A. Ono, E. O. Freed, W.-S. Hu, and V. K. Pathak. 2004. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279:35822-35828.
64. Tosi, M. F. 2005. Innate immune responses to infection. J. Allergy Clin. Immunol. 116:241-249.
65. Turelli, P., B. Mangeat, S. Jost, S. Vianin, and D. Trono. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829.
66. Turelli, P., S. Vianin, and D. Trono. 2004. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 279:43371-43373.
67. von Schwedler, U., J. Song, C. Aiken, and D. Trono. 1993. Vif crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:4945-4955.
68. Wedekind, J. E., G. S. C. Dance, M. P. Sowden, and H. C. Smith. 2003. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19:207-216.
69. Wiegand, H. L., B. P. Doehle, H. P. Bogerd, and B. R. Cullen. 2004. A second human antiretroviral factor. APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458.
70. Yoshikawa, K., I. M. Okazaki, T. Eto, K. Kinoshita, M. Muramatsu, H. Nagaoka, and T. Honjo. 2002. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 296:2033-2036.
71. Yu, Q., D. Chen, D., R. König, R. Mariani, D. Unutmaz, and N. R. Landau. 2004. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279:53379-53386.
72. Yu, Q., R. König, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J. M. Coffin, and N. R. Landau. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442.
73. Yu, X., Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X.-F. Yu. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
74. Yu, Y., Z. Xiao, E. S. Ehrlich, X. Yu, and X.-F. Yu. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872.
75. Zennou, V., D. Perez-Caballero, H. Göttlinger, and P. D. Bieniasz. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78:12058-12061.
76. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
77. Zhang, J., and D. M. Webb. 2004. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 13:1785-1791.
78. Zheng, Y.-H., D. Irwin, T. Kurosu, K. Tokunaga, T. Sata, and B. M. Peterlin. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073-6076.